gallocatechin-3-gallate and baicalein

The emergence of severe acute syndrome coronavirus 2 (SARS-CoV-2) in December 2019 has led to the global COVID-19 pandemic. Although the symptoms of most COVID-19 patients are mild or self-curable, most of severe patients have sepsis caused by cytokine storms, which greatly increases the case fatality rate. Moreover, there is no effective drug that can limit the novel coronavirus thus far, so it is more needed to develop antiviral drugs for the SARS-CoV-2. In our research, we employed the techniques of molecular docking to screen 35 flavonoid compounds among which 29 compounds have Z-scores lower than - 6. Then, ( -)-gallocatechin gallate, ( +)-gallocatechin and baicalein were identified to have potent inhibitory activity against SARS-CoV-2 M

Topics: Animals; Antiviral Agents; Catechin; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytokine Release Syndrome; Flavanones; Humans; Mice; Molecular Docking Simulation; Pandemics; Protease Inhibitors; SARS-CoV-2; Sepsis